PHIO
Phio Pharmaceuticals Corp.
$1.07
-0.93%
$12.4M
No data for this timeframe.
Vol
Market Cap$12.4M
Cap SizeNano Cap
Inst. Holders8 funds
Inst. Value$204.6K
Inst. Activity2 buys / 0 sells
SEC Reports3
Recent Activity
Apr 8, 2026
SEC
Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 mil
8-K — Impact 5/10
Apr 8, 2026
SEC
Phio Pharmaceuticals is conducting an at-the-market offering of up to $6.36 million in common stock through H.C. Wainwri
424B5 — Impact 5/10
Mar 5, 2026
SEC
Phio Pharmaceuticals reported its 2025 financial results, highlighting a successful year with completion of the PH-762 P
8-K — Impact 6/10
Feb 5, 2026
Insider
BRADFORD PATRICIA A was granted 18,500 shares
Director
Feb 5, 2026
Insider
Bitterman Robert J was granted 120,000 shares
Chairman, Pres. & CEO
Feb 5, 2026
Insider
Carson Lisa Cabott was granted 47,000 shares
Chief Financial Officer
Inst.
VANGUARD GROUP INC — ADD
87,628 shares ($217.3K)
Inst.
BANK OF AMERICA CORP — DOUBLED
1,400 shares ($3.5K)
Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$14.00 (Feb 2026)
Current $1.07
Low $14.00
Median $14.00
High $14.00
1 analysts
$14.00
$14.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.36 ▼ -53.2% | $-0.37 — $-0.35 | 2 | |
| Next Q | $-0.33 ▼ -35.4% | $-0.34 — $-0.31 | 26% YoY | 2 |
| Current FY | $-1.38 ▼ -44.7% | $-1.40 — $-1.35 | 5% YoY | 2 |
| Next FY | $-0.86 ▼ -38.7% | $-0.91 — $-0.81 | 37% YoY | 2 |
Latest Reports
NEUTRAL
8-K
5/10
Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to sell up to $6.36 mil
Apr 8, 2026
NEUTRAL
424B5
5/10
Phio Pharmaceuticals is conducting an at-the-market offering of up to $6.36 million in common stock through H.C. Wainwri
Apr 8, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD CAPITAL MANAGEMENT LLC | $97.4K | — |
| VANGUARD FIDUCIARY TRUST CO | $46.6K | — |
| TWO SIGMA INVESTMENTS, LP | $39.6K | — |
| CAPTRUST FINANCIAL ADVISORS | $12.2K | — |
| MORGAN STANLEY | $7.3K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 5, 2026 | BRADFORD PATRICIA | A | $0.00 |
| Feb 5, 2026 | Bitterman Robert | A | $0.00 |
| Feb 5, 2026 | Carson Lisa | A | $0.00 |
| Feb 5, 2026 | Deming David | A | $0.00 |
| Feb 5, 2026 | Freeman Jonathan | A | $0.00 |
8 institutional holders with $204.6K total value (202,384 shares) as of 2026-Q1. Top holders: VANGUARD, VANGUARD, TWO.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 79,853 | $97.4K | 47.6% | — |
| 2 | VANGUARD FIDUCIARY TRUST CO | 38,169 | $46.6K | 22.8% | — |
| 3 | TWO SIGMA INVESTMENTS, LP | 32,495 | $39.6K | 19.4% | — |
| 4 | CAPTRUST FINANCIAL ADVISORS | 10,000 | $12.2K | 6.0% | — |
| 5 | MORGAN STANLEY | 6,000 | $7.3K | 3.6% | — |
| 6 | CITIGROUP INC | 1,025 | $1.3K | 0.6% | — |
| 7 | ASSETMARK, INC | 110 | $134.00 | 0.1% | — |
| 8 | HRT FINANCIAL LP | 34,732 | $42.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | ADD | 48,665 | 87,628 | +80.1% | $217.3K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 46 | 1,400 | +2943.5% | $3.5K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 2,397 | 103 | -95.7% | $134.00 | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 7 | 41 | +485.7% | $53.00 | 2025-Q1 |
| UBS Group AG | ADD | 1,685 | 2,397 | +42.3% | $4.3K | 2024-Q4 |
6 unique insiders with 6 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Feb 5, 2026 | BRADFORD PATRICIA A | Director | AWARD | 18,500 | — | — |
| Feb 5, 2026 | Bitterman Robert J | Chairman, Pres. & CEO | AWARD | 120,000 | — | — |
| Feb 5, 2026 | Carson Lisa Cabott | Chief Financial Officer | AWARD | 47,000 | — | — |
| Feb 5, 2026 | Deming David H | Director | AWARD | 23,800 | — | — |
| Feb 5, 2026 | Freeman Jonathan E | Director | AWARD | 16,600 | — | — |
| Feb 5, 2026 | Lockshin Curtis | Director | AWARD | 16,600 | — | — |
3 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 5.3/10.
NEUTRAL
8-K
5/10
Phio Pharmaceuticals entered into an at-the-market offering agreement with H.C. Wainwright & Co. to
Apr 8, 2026
NEUTRAL
424B5
5/10
Phio Pharmaceuticals is conducting an at-the-market offering of up to $6.36 million in common stock
Apr 8, 2026
MIXED
8-K
6/10
Phio Pharmaceuticals reported its 2025 financial results, highlighting a successful year with comple
Mar 5, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Feb 2026): 86% buy across 7 analysts — 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Feb 2026. No current recommendation available.
$14.00 mean target (Feb 2026)
$14.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $1.07 |
| Target Low | $14.00 |
| Target Mean | $14.00 |
| Target Median | $14.00 |
| Target High | $14.00 |
| # Analysts | 1 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.36 | $-0.37 | $-0.35 | — | -53.2% | 0↑ 2↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.33 | $-0.34 | $-0.31 | 26.1% | -35.4% | 0↑ 2↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-1.38 | $-1.40 | $-1.35 | 5.2% | -44.7% | 0↑ 2↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-0.86 | $-0.91 | $-0.81 | 37.5% | -38.7% | 0↑ 2↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.360 | |
| 7d ago | $-0.235 | -0.125 |
| 30d ago | $-0.235 | -0.125 |
| 60d ago | $-0.235 | -0.125 |
| 90d ago | $-0.300 | -0.060 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Feb 10, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 13, 2026
earnings_calendar
PHIO Q1 2026 Earnings Scheduled — 2026-05-13
Feb 12, 2026
short_interest
FTD: PHIO — 776,176 shares ($1.0M) failed to deliver
Settlement: 20260212, Price: $1.29, FTD Value: $1,001,267.04, PHIO PHARMACEUTICALS CORP COM
Feb 11, 2026
short_interest
FTD: PHIO — 2,311,187 shares ($2.6M) failed to deliver
Settlement: 20260211, Price: $1.12, FTD Value: $2,588,529.44, PHIO PHARMACEUTICALS CORP COM